IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY

IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY

Abstract BACKGROUND The polio:rhinovirus chimera, PVSRIPO, and the herpes simplex virus, G207, are viral immunotherapies with promising results in Phase I trials of pediatric high-grade glioma (pHGG) and medulloblastoma. While some patients have durable responses, others have no benefit. The purpose...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2023-06, Vol.25 (Supplement_1), p.i49-i49
Hauptverfasser: Thompson, Eric, Kang, Kyung-Don, Zhang, Hengshan, Brown, Michael, Stevenson, Kevin, Friedman, Gregory
Format: Artikel
Sprache:eng
Schlagworte:
Final Category: Immunology/Immunotherapy - IMMU
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page i49
container_issue Supplement_1
container_start_page i49
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 25
creator Thompson, Eric
Kang, Kyung-Don
Zhang, Hengshan
Brown, Michael
Stevenson, Kevin
Friedman, Gregory
description Abstract BACKGROUND The polio:rhinovirus chimera, PVSRIPO, and the herpes simplex virus, G207, are viral immunotherapies with promising results in Phase I trials of pediatric high-grade glioma (pHGG) and medulloblastoma. While some patients have durable responses, others have no benefit. The purpose of this study is to identify genes that putatively confer resistance to viral immunotherapy. METHODS A panel of medulloblastoma and pHGG cell lines were treated with either PVSRIPO or G207 and categorized into “sensitive” and “resistant” groups based viability. Flow cytometry was used to quantify cell receptor expression (CD111 for G207, CD155 for PVSRIPO). RNA sequencing was completed on treated resistant and sensitive cells. RESULTS D341 and D556 medulloblastoma had < 50% viability at 72h (G207) and 24h (PVSRIPO) and were categorized as sensitive; D283 and D324 were categorized as resistant. There was a correlation between CD111 expression and cell viability (Spearman r=0.71) but no correlation between CD155 and viability. The number of significantly differentially expressed (DE) genes (adjusted p≤0.05) was significantly higher in sensitive compared to resistant medulloblastoma, both for enriched (mean 666.4±614 vs. 454.6±377.4, P=0.0422) and depleted (826.9±645.5 vs. 449±367.8, P=0.0167) genes after treatment. There were few shared DE genes between cells treated with PVSRIPO and G207: GCLM, LANCL2, and RBM3 were enriched while ADAMTS1 and VEGFA were depleted. Likewise, there were few shared DE genes enriched between medulloblastoma and pHGG cell lines treated with G207: GPSM2, CHECK2, SEPTIN2, EIF4G2, GCLM, GDAP1, LANCL2, and PWP1. CONCLUSIONS Genetic analysis demonstrates minimal overlap in DE genes between the two viral immunotherapies. PVRIPO and G207 infection resulted in significantly more DE gene expression in sensitive vs. resistant cells. GCLM and LANCL2 are enriched by both PVSRIPO and G207 and in medulloblastoma and pHGG. These genes may serve as potential biomarkers in predicting response to viral immunotherapy.
doi_str_mv 10.1093/neuonc/noad073.190
format Article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10260184</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noad073.190</oup_id><sourcerecordid>10.1093/neuonc/noad073.190</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1810-dcb302ae1ffd766f25e90e08952c5373736eea0bf60b0854c3cf9a3b6f9535563</originalsourceid><addsrcrecordid>eNqNkMFOwkAQhhujiYi-gKd9gcLsLrttvRiEhW6EbtMWEk-btmwVAy1pxcS3t1hi4s3MYSYz8_9_8lnWPYYBBo8OS3OsynxYVukGHDrAHlxYPcwItZnL-eXPTGyXYefaummadwCCGcc9q5bL5coGOkByKoJEzuRknEgVIDVDcxGIRE7Qk1TLcfQsohglCoWRmMpJgiIRhyqIxWnnx2sbozkBB42DKQrVQqqHyJeBWstoFaNTSKASX0Tj8OXWuirSXWPuzr1vrWYimfj2Qs3b9IWdYxeDvckzCiQ1uCg2DucFYcYDA67HSM6o0xY3JoWs4JCBy0Y5zQsvpRkvPEYZ47RvPXa-h2O2N5vclB91utOHertP6y9dpVv991Ju3_Rr9akxEA7YHbUOpHPI66ppalP8ijHoE3fdcddn7rrl3orsTlQdD__5_wYcj4BA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Thompson, Eric ; Kang, Kyung-Don ; Zhang, Hengshan ; Brown, Michael ; Stevenson, Kevin ; Friedman, Gregory</creator><creatorcontrib>Thompson, Eric ; Kang, Kyung-Don ; Zhang, Hengshan ; Brown, Michael ; Stevenson, Kevin ; Friedman, Gregory</creatorcontrib><description>Abstract BACKGROUND The polio:rhinovirus chimera, PVSRIPO, and the herpes simplex virus, G207, are viral immunotherapies with promising results in Phase I trials of pediatric high-grade glioma (pHGG) and medulloblastoma. While some patients have durable responses, others have no benefit. The purpose of this study is to identify genes that putatively confer resistance to viral immunotherapy. METHODS A panel of medulloblastoma and pHGG cell lines were treated with either PVSRIPO or G207 and categorized into “sensitive” and “resistant” groups based viability. Flow cytometry was used to quantify cell receptor expression (CD111 for G207, CD155 for PVSRIPO). RNA sequencing was completed on treated resistant and sensitive cells. RESULTS D341 and D556 medulloblastoma had &lt; 50% viability at 72h (G207) and 24h (PVSRIPO) and were categorized as sensitive; D283 and D324 were categorized as resistant. There was a correlation between CD111 expression and cell viability (Spearman r=0.71) but no correlation between CD155 and viability. The number of significantly differentially expressed (DE) genes (adjusted p≤0.05) was significantly higher in sensitive compared to resistant medulloblastoma, both for enriched (mean 666.4±614 vs. 454.6±377.4, P=0.0422) and depleted (826.9±645.5 vs. 449±367.8, P=0.0167) genes after treatment. There were few shared DE genes between cells treated with PVSRIPO and G207: GCLM, LANCL2, and RBM3 were enriched while ADAMTS1 and VEGFA were depleted. Likewise, there were few shared DE genes enriched between medulloblastoma and pHGG cell lines treated with G207: GPSM2, CHECK2, SEPTIN2, EIF4G2, GCLM, GDAP1, LANCL2, and PWP1. CONCLUSIONS Genetic analysis demonstrates minimal overlap in DE genes between the two viral immunotherapies. PVRIPO and G207 infection resulted in significantly more DE gene expression in sensitive vs. resistant cells. GCLM and LANCL2 are enriched by both PVSRIPO and G207 and in medulloblastoma and pHGG. These genes may serve as potential biomarkers in predicting response to viral immunotherapy.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noad073.190</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Final Category: Immunology/Immunotherapy - IMMU</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2023-06, Vol.25 (Supplement_1), p.i49-i49</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260184/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260184/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27911,27912,53778,53780</link.rule.ids></links><search><creatorcontrib>Thompson, Eric</creatorcontrib><creatorcontrib>Kang, Kyung-Don</creatorcontrib><creatorcontrib>Zhang, Hengshan</creatorcontrib><creatorcontrib>Brown, Michael</creatorcontrib><creatorcontrib>Stevenson, Kevin</creatorcontrib><creatorcontrib>Friedman, Gregory</creatorcontrib><title>IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract BACKGROUND The polio:rhinovirus chimera, PVSRIPO, and the herpes simplex virus, G207, are viral immunotherapies with promising results in Phase I trials of pediatric high-grade glioma (pHGG) and medulloblastoma. While some patients have durable responses, others have no benefit. The purpose of this study is to identify genes that putatively confer resistance to viral immunotherapy. METHODS A panel of medulloblastoma and pHGG cell lines were treated with either PVSRIPO or G207 and categorized into “sensitive” and “resistant” groups based viability. Flow cytometry was used to quantify cell receptor expression (CD111 for G207, CD155 for PVSRIPO). RNA sequencing was completed on treated resistant and sensitive cells. RESULTS D341 and D556 medulloblastoma had &lt; 50% viability at 72h (G207) and 24h (PVSRIPO) and were categorized as sensitive; D283 and D324 were categorized as resistant. There was a correlation between CD111 expression and cell viability (Spearman r=0.71) but no correlation between CD155 and viability. The number of significantly differentially expressed (DE) genes (adjusted p≤0.05) was significantly higher in sensitive compared to resistant medulloblastoma, both for enriched (mean 666.4±614 vs. 454.6±377.4, P=0.0422) and depleted (826.9±645.5 vs. 449±367.8, P=0.0167) genes after treatment. There were few shared DE genes between cells treated with PVSRIPO and G207: GCLM, LANCL2, and RBM3 were enriched while ADAMTS1 and VEGFA were depleted. Likewise, there were few shared DE genes enriched between medulloblastoma and pHGG cell lines treated with G207: GPSM2, CHECK2, SEPTIN2, EIF4G2, GCLM, GDAP1, LANCL2, and PWP1. CONCLUSIONS Genetic analysis demonstrates minimal overlap in DE genes between the two viral immunotherapies. PVRIPO and G207 infection resulted in significantly more DE gene expression in sensitive vs. resistant cells. GCLM and LANCL2 are enriched by both PVSRIPO and G207 and in medulloblastoma and pHGG. These genes may serve as potential biomarkers in predicting response to viral immunotherapy.</description><subject>Final Category: Immunology/Immunotherapy - IMMU</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqNkMFOwkAQhhujiYi-gKd9gcLsLrttvRiEhW6EbtMWEk-btmwVAy1pxcS3t1hi4s3MYSYz8_9_8lnWPYYBBo8OS3OsynxYVukGHDrAHlxYPcwItZnL-eXPTGyXYefaummadwCCGcc9q5bL5coGOkByKoJEzuRknEgVIDVDcxGIRE7Qk1TLcfQsohglCoWRmMpJgiIRhyqIxWnnx2sbozkBB42DKQrVQqqHyJeBWstoFaNTSKASX0Tj8OXWuirSXWPuzr1vrWYimfj2Qs3b9IWdYxeDvckzCiQ1uCg2DucFYcYDA67HSM6o0xY3JoWs4JCBy0Y5zQsvpRkvPEYZ47RvPXa-h2O2N5vclB91utOHertP6y9dpVv991Ju3_Rr9akxEA7YHbUOpHPI66ppalP8ijHoE3fdcddn7rrl3orsTlQdD__5_wYcj4BA</recordid><startdate>20230612</startdate><enddate>20230612</enddate><creator>Thompson, Eric</creator><creator>Kang, Kyung-Don</creator><creator>Zhang, Hengshan</creator><creator>Brown, Michael</creator><creator>Stevenson, Kevin</creator><creator>Friedman, Gregory</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20230612</creationdate><title>IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY</title><author>Thompson, Eric ; Kang, Kyung-Don ; Zhang, Hengshan ; Brown, Michael ; Stevenson, Kevin ; Friedman, Gregory</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1810-dcb302ae1ffd766f25e90e08952c5373736eea0bf60b0854c3cf9a3b6f9535563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Final Category: Immunology/Immunotherapy - IMMU</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Eric</creatorcontrib><creatorcontrib>Kang, Kyung-Don</creatorcontrib><creatorcontrib>Zhang, Hengshan</creatorcontrib><creatorcontrib>Brown, Michael</creatorcontrib><creatorcontrib>Stevenson, Kevin</creatorcontrib><creatorcontrib>Friedman, Gregory</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, Eric</au><au>Kang, Kyung-Don</au><au>Zhang, Hengshan</au><au>Brown, Michael</au><au>Stevenson, Kevin</au><au>Friedman, Gregory</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2023-06-12</date><risdate>2023</risdate><volume>25</volume><issue>Supplement_1</issue><spage>i49</spage><epage>i49</epage><pages>i49-i49</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract BACKGROUND The polio:rhinovirus chimera, PVSRIPO, and the herpes simplex virus, G207, are viral immunotherapies with promising results in Phase I trials of pediatric high-grade glioma (pHGG) and medulloblastoma. While some patients have durable responses, others have no benefit. The purpose of this study is to identify genes that putatively confer resistance to viral immunotherapy. METHODS A panel of medulloblastoma and pHGG cell lines were treated with either PVSRIPO or G207 and categorized into “sensitive” and “resistant” groups based viability. Flow cytometry was used to quantify cell receptor expression (CD111 for G207, CD155 for PVSRIPO). RNA sequencing was completed on treated resistant and sensitive cells. RESULTS D341 and D556 medulloblastoma had &lt; 50% viability at 72h (G207) and 24h (PVSRIPO) and were categorized as sensitive; D283 and D324 were categorized as resistant. There was a correlation between CD111 expression and cell viability (Spearman r=0.71) but no correlation between CD155 and viability. The number of significantly differentially expressed (DE) genes (adjusted p≤0.05) was significantly higher in sensitive compared to resistant medulloblastoma, both for enriched (mean 666.4±614 vs. 454.6±377.4, P=0.0422) and depleted (826.9±645.5 vs. 449±367.8, P=0.0167) genes after treatment. There were few shared DE genes between cells treated with PVSRIPO and G207: GCLM, LANCL2, and RBM3 were enriched while ADAMTS1 and VEGFA were depleted. Likewise, there were few shared DE genes enriched between medulloblastoma and pHGG cell lines treated with G207: GPSM2, CHECK2, SEPTIN2, EIF4G2, GCLM, GDAP1, LANCL2, and PWP1. CONCLUSIONS Genetic analysis demonstrates minimal overlap in DE genes between the two viral immunotherapies. PVRIPO and G207 infection resulted in significantly more DE gene expression in sensitive vs. resistant cells. GCLM and LANCL2 are enriched by both PVSRIPO and G207 and in medulloblastoma and pHGG. These genes may serve as potential biomarkers in predicting response to viral immunotherapy.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noad073.190</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2023-06, Vol.25 (Supplement_1), p.i49-i49
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10260184
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Final Category: Immunology/Immunotherapy - IMMU
title IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T21%3A37%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IMMU-03.%20IDENTIFICATION%20OF%20GENETIC%20BIOMARKERS%20TO%20PREDICT%20RESPONSE%20TO%20HSV-1%20G207%20AND%20POLIO:RHINOVIRUS%20IMMUNOTHERAPY&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Thompson,%20Eric&rft.date=2023-06-12&rft.volume=25&rft.issue=Supplement_1&rft.spage=i49&rft.epage=i49&rft.pages=i49-i49&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noad073.190&rft_dat=%3Coup_pubme%3E10.1093/neuonc/noad073.190%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noad073.190&rfr_iscdi=true